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Background: The current staging system of hepatocel-
lular carcinoma established by the International Union 
Against Cancer and the American Joint Committee on 
Cancer does not necessarily predict the outcomes aher 
hepatic resection or transplantation. 
Study a~sign: Various clinical and pathologic risk fac-
tors for tumor recurrence were examined on 344 con-
secutive patients who received hepatic transplantation 
in the presence of nonfibrolamellar hepatocellular car-
cinoma to establish a reliable risk scoring system. • 
191:389-394. 
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The current staging system of hepatocellular carci-
noma (HCC) established by the International 
Union Against Cancer! and the American Joint 
Committee on Cancer2 does not necessarily predict 
the outcomes after hepatic resection or transplanta-
tion.3.4 Although modifications of the current sys-
tem have been suggested,3,S,6 they are not widely 
accepted because of their complexity. 
Various clinical and pathologic risk factors for 
tumor recurrence and mortality were examined on 
344 consecutive patients who underwent hepatic 
transplantation in the presence ofHCC to establish 
a prognostic scoring system of HCC that can pre-
dict the prognosis after liver transplantation better 
than the current staging system. 1,2 
Results: Multivariate analysis iden"tified three factors as 
independently significant poor prognosticators: 1) bi-
lobarly distributed tumors, 2) size of the greatest tu-
mor (2 to 5 cm and> 5 cm), and 3) vascular invasion 
(microscopic and macroscopic). Prognostic risk score 
(PRS) of each patient was calculated from the relative 
risks of multivariate analysis. The patients were 
grouped into five grades of tumor recurrence risk: 
grade 1: PRS=O to <7.5; grade 2: PRS=7.5 toS 
11.0; grade 3: PRS> 11.0 to 15.0; grade 4: PRS > METHODS 
15.0; and grade 5: positive node, metastasis, or margin. During the IS-year period between .1981 and 1998, 
The proposed PRS system correlated extremely well 344 consecutive patients underwent orthotopic 
with tumor-free survivalaher liver transplantation liver transplantation in the presence of H CC at the 
(100%, 61 %, 40%, 5%, and 0%, from grades 1 to 5, University of Pittsburgh Medical Center. Fibrola-
respectively,at?years),butcurrentpTNMstagingdid mellar variant of HCC was. excluded from this 
not. study because this variant carried a better prognosis 
Conclusions: 1) Patients with grades 1 and 2 are effec- than ordinary HCC/ Basic immunosuppressive 
tively treated with liver transplantation, 2) patients therapies were cyclosporine and steroi~ before 
with grades 4 and 5 are poor candidates for liver trans-. 1989, and tacrolrmus replaced cyclosponne after 
plantation, and 3) patients with grade 1 do not benefit ;1989. 
from adjuvant chemotherapy. (J Am ColI Surg 2000; All surviving patients were followed closely at 
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the outpatient clinic and the tumor recurrence was 
monitored by a-fetoprotein and CT every 
3 months for the first 3 years and semiannually 
thereafter. Suspicious lesions were biopsied for con-
firmation of recurrence. 
There were 257 men and 87 women. Their ages 
ranged from 2.8 to 76.8 years (mean ± SD: 52.9 ± 
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i 3.3 years). In 317 of the 344 patients HCC devel-
oped in the cirrhotic liver, and in the remaining 27 
patients it developed in the noncirrhotic liver. Hep-
atitis B surface antigen (HB,Ag) was positive in 75 
of the 344 patients and antihepatitis C virus anti-
body (HCV-Ab) was positive in 105 of the 221 
patients tested. 
The most common cause of the associated liver 
disease was HCV-Ab-positive cirrhosis (94 pa-
tients), followed by HB,Ag-positive cirrhosis (58 
patients) and alcoholic cirrhosis (49 patients). In 
addition there were 11 cirrhotic patients who tested 
positive for both HB,Ag and HCV antibodies. 
There were 59 patients of so-called non-A, non-B 
cirrhosis, which was diagnosed before testing of 
HCV-Ab became available. Other liver diseases in-
cluded inborn errors of tnetabolism (hemochroma-
tosis, tyrosinemia, a-I antitrypsin deficiency, and 
others; 23 patients), primary biliary cirrhosis (9 pa-
tients), autoimmune hepatitis (9 patients), biliary 
atresia (3 patients), and other various diseases (11 
patients). The remaining 18 patients with HCC did 
not have any associated liver disease. 
The size of HCC ranged from 0.3 to 25.0 cm 
(mean ± SD: 4.1 ± 4.1 cm). The number of gross 
tumors ranged from one to five (mean ± SD: 
2.22 ± 1.47). The tumors w~re distributed bilo-
barly in 108 patients and unilobarly in 236 patients. 
Microscopic examination of HCC revealed well-
differentiated tumor in 94 patients, moderately dif-
ferentiated in 224 patients, and poorly differenti-
ated in 26 patients. The HCC invaded vessels 
macroscopically in 62 patients and microscopically 
in 87 patients. The tumor did not show any vascu-
lar invasion in 195 patients. Regional lymph node 
was involved by tumor in 9 patients and' was not 
involved in 335 patients. Metastatic lesions were 
present in 18 patients (diaphragm, omentum, ex-
trahilar node) and were absent in 326 patients. Al-
though all gross tumors were removed, postopera-
tive pathologic examination revealed that surgical 
margins were microscopically involved by tumor in 
18 patients and were not involved in 326 patients. 
Chemotherapy was administered before trans-
plantation in 46 patients (including the 34 patients 
with intraarterial chemotherapy) and it was given 
after transplantation but before tumor recurrence in 
29 patients. The chemotherapeutic regimens were 
highly variable because of the prolonged study period. 
The results were summarized as of April 1 , 1999 
with -a median followup period of91.0 ± 44.9 (SD) 
months. Survival curves were generated by the 
method of Kaplan-Meier and were compared using 
the log-rank test. A multivariate stepwise Cox's re-
gression analysis (backward elimination method) 
was performed to identify the factors that were in-
dependently associated with mortality and tumor 
recurrence. A two-sided p value of< 0.05 was con-
sidered statistically significant. 
RESULTS 
Overall patient and tumor-free survivals 
As of April 1, 1999, 145 patients were alive, free of 
HCC; 5 patients were alive with recurrent flCC; 
104 patients were dead without HCC; 78 patients 
were dead with recurrent HCCj and 12 patients 
were lost to followup (they were free of recurrence at 
the last followup). One-, 3-, 5-, and 10-year overall 
patient survivals were 73.0 ± 2.4% (SE), 58.8 ± 
2.8%, 49.4±3.0%, and 32.7±3.9%, respectively, 
and those of tumor-free survivals were 81.9 ± 
2.3%, 73.0 ± 2.8%, 68.7 ± 3.0%, and 64.4 ± 
4.0%, respectively. ,i;. 
Clinical and pathologic risk factors of mortality 
and tumor recurrence 
Tu.mor recurrence developed within 2 years after 
transplantation in all of the 26 patients who had 
lymph node involvement, metastasis, or positive 
microscopic surgical margins. These 26 patients 
. with lethal risk factors were excluded from addi-
tional analysis but they were considered as a lethal 
risk group, or noncandidates for transplantation. 
The results of univariate analysis on the 11 risk 
factors in the remaining 318 patients (excluding 26 
patients with lethal factors) are shown in Table 1. 
Tumor number, size, lobar distribution, vascular in-
vasion, and differentiation were significant risk fac-
tors of both patient survival and tumor-free sur-
vival. Positive HB,Ag was a significant risk factor of 
tumor-free survival, but it was not a significant risk 
factor of patient survival. Anecdotally, positive 
. HCV-Ab was a significant good prognostic factor 
both in patient and tumor-free survival. Additional 
examination revealed that significantly more pa-
tients with positive HB,Ag were included in the 
HCV-Ab-negative patients than in the HCV-Ab-
positive patients (p< 0.03). When the patients with 
b 
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Table 1. Influences of Various Clinicopathologic Risk Factors on Overall Patient and Tumor-Free 
Survival (Univariate Analysis) 
Patient survival (y) 
Risk factor n Mean ± SE 
Gender' 
Male 235 -6.9 ± 0.5 
Female 83 8.6 ± 0.9 
Age (y) 
::; 65 277 7.8 ± 0.5 
> 65 41 5.4 ± 0.7 
HB.Ag < 
Positive 66 5.4 ± 0.6 
Negative 252 7.5 ± 0.5 
HCVantibody 
Positive 101 7.0 ± 0.4 
Negative 111 5.2 ± 0.4 
No. of tumors 
1-2 221 9.4 ± 0.9 
3-4 68 7.1 ± 0.6 
;:::5 29 4.2 ± 1.3 
Distribution 
Unilobar 232 8.8 ± 0.6 
Bilobar 86 4.3 ± 0.5 
Tumor size 
;:::2cm 149 7.2 ± 0.6 
2-5 cm 108 8.0 ± 0.8 
>5 61 4.9 ± 0.8 
Vascular invasion 
VO (none) ,)95 9.1 ± 0.6 
VI (micro) 80 7.8 ± 0.9 
V2 (macro) 43 1.7 ± 0.3 
Differentiation 
Good 94 9.4 ± 0.9 
Moderate '205 7.1 ± 0.6 
Poor 19 4.2 ± 1.3 
Cirrhosis 
Yes 300 8.0 ± 0.5 
No 18 3.8 ± 0.5 
Chemotherapy 
Yes 64 5.9 ± 0.6 -
No 254 7.8 ± 0.5 
HB,Ag, hepatitis B surface antigen; HCV, hepatitis C virus. 
positive eB~g were excluded, both patient and 
tumor-free survivals were similar between HCV-
Ab-positive and -negative patients. The absence of 
cirrhosis and the use of neoadjuvant/adjuvant che-
motherapywere significant poor prognostic factors. 
The HCCs in the noncirrhotic liver and the HCCs 
treated with chemotherapy were disproportionately 
more advanced than those in the cirrhotic liver or 
those without chemotherapy, respectively. 
The results of multivariate analysis of the fac-
tors that were significant by univariate analysis for 
tumor-free survival and those of patient survival are 
Tumor-free survival (y) 
p Value Mean ± SE p Value 
NS 10.3 ± 0.5 NS 
12.5 ± 0.8 
NS 11.7 ± 0.5 NS 
8.2 ± 0.8 
NS 6.8 ± 0.7 < 0.002 
12.6 ± 0.5 
< 0.001 9.0 ± 0.3 < 0.0001 
6.8 ± 0.3 
13.9 ± 0.5 
< 0.00001 7.8 ± 1.1 <00001 
3.9 ± 1.0 
< 0.0001 14.0 ± 0.5 < 0.00001 
5.0 ± 0.6 
11.6±0.5 
< 0.007 10.9 ± 0.8 <"0.00001 
6.4 ± 1.1 
14.8 ± 0.5 
< 0.00001 10.0 ± 0.9 < 0.00001 
1.5 ± 0.4 
14.0 ± 0.7 
< 0.002 10.9 ± 0.6 < 0.002 
7.0 ± 2.1 
< 0.02 12.1 ±0.5 < 0.0001 
4.2 ± 1.3 
NS 6.6 ± 0.7 < 0.002 
12.8 ± 0.5 
shown in Tables 2 and 3, respectively, with relative 
risk and 95% confidence interval. For tumor-free 
survival, bilobar tumors, large tumor size (> 2 em, • 
> 5 em), and the presence of vascular invasion 
(micro- and macroscopic) were independently sig-
nificant poor prognostic factors. For patient sur-
vival the number of tumor~ and vascular invasion 
were independently significant prognostic factors. 
Risk scores for tumor recurrence 
Using the relative risks obtained by the Cox regres-
sion analysis (Table 2), the risk score of tumor re-
, , 
! 
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Table 2. Risk Factors of Tumor-Free Survival Found 
to Be Significant (p < 0.05) by Backward Cox 
Proportional Hazard Regression (Multivariate 
Analysis) 
Variable RR 95% CI 
--~~--~~~--~~~~~~~~--
Bilobar tumor (p < 0.000l) 3.1 [1.7,5.4] 
Compared with unilobar 
Tumor size (p < 0.0003) 
Compared with size ::5 2 em 
2-5 cm 
> 5 cm 
Vascular invasion (p < oeo1) 
Compared with none 
Micro 
Macro 
CI, confidence interval; RR relative risk. 
4.5 
6.7 
4.4 
15.0 
[1.5, 13.0] 
[2.2, 19.9J 
[2.1,9.5] 
[6.7,33.8] 
currence was calculated additively on each patient 
who had negative surgical margins, no lymph node 
invasion, or no metastasis. The risk scores ranged 
from 0 (none of the three risk factors present) to 
24.8 (all of the three risk factors present at the high-
est level) and was a monotonous function of the 
likelihood of tumor recurrence. The mean risk score 
was 6.8 ± 7.4 (SD). The risk scores were computed 
and the various groups of risk scores were searched 
to fulfill that the number of groups with distinctly 
different outcomes was maximized while the vari-
ance of outcomes inside each group was minimizeCl. 
The following five groups of risk scores satisfied the 
criteria mentioned earlier: grade 1: risk score 0 to < 
7.5; grade 2: risk score 7.5 to< 11.0; grade 3: risk 
score> 11.0 to 15.0; and grade 4: risk score > 15.0. 
The final group (grade 5) consisted of the patients 
who had positive surgical margins, lymph node, or 
distant metastasis (Table 4). 
The actuarial tumor-free survivals df the five 
grades of risk scores are shown in Figure 1. Five-year 
tumor-free survivals of grades 1 to 5 were 100%, 
61 %,40%,5%, and 0%, respectively. It should be 
noted that the differences in survivals are statisti--
cally significant in any comparison. 
Table 4. Prognostic Risk Score Grading for Tumor 
Recurrence 
Grade 1 . 0 ::5 Risk score < 7.5 
Grade 2 7.5::5 Risk score ::511.0 
Grade 3 11.0 < Risk score < 15.0 
Grade 4 Risk score;::: 15.0 
Grade 5 Positive margin, lymph node, or metastasis 
Table 3. Risk Factors of Overall Survival Found 
to Be Significant (p < 0.05) by Backward Cox 
Proportional Hazard Regression (Multivariate 
Analysis) 
Variable RR 95% CI 
No. of tumors (p < 0.02) 
Compared with 1-2 
3-4 1.4 [0.9,2.1] 
>4 2.1 [1.3, 3.5] 
Vascular invasion (p < 0.0001) 
Compared with none 
Micro 1.1 [0.7, 1".7J 
Macro 3.5 [2.2, 5.4] 
CI, confidence interval; RR relative risk. 
DISCUSSION 
Various risk factors for tumor recurrence and mor-
tality after hepatic resection and transplantation for 
HCC have been identified in numerous reports,8-19 
but there has been no prognostic scoring system 
that can reliably predict HCC recurrence after sur-
gical treatment. The development of such a system 
for subtotal hepatectomy is more complex than that 
for total hepatectomy with replacement (orthotopic 
liver transplantation), because in the former de 
novo HCCs and metastatic HCCs constitute tu-
mor recurrence. After liver replacement de novo 
HCCs are extremely rare and the prediction of tu-
mor recurrence should be possible only from the 
metastic potential of the treated HCCs. 
In this study various clinical and pathologic risk 
factors were examined in 344 patients and the three 
risk factors were found to be independently signif-
icant for tumor recurrence. The risk score was cal-
culated in each patient by addIng the relative risk of 
the Cox proportional model, and the scores were 
grouped into four grades. An additional group con-
sisted of the patients who had positive surgical mar-
gin, lymph node, or metastasis. The tumor-free sur-
vivals of these five grades of risk scores are 
significantly different from each other (Fig. 1). 
Tumor-free survivals of our 326 patients with neg-
ative surgical margins are stratified by pTNM stag-
es l .2 and are shown in Figure 2. It is quite evident 
that pTNM staging does not correlate with tumor-
free survival after liver transplantation: the tumor-
free survivals of patients in stages I to III-A were 
similar. 
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Figure 1. Actuarial tumor-free survival stratified ey proposed risk score grading. 
Our proposed scoring system must be verified 
by a large number of patients at other major centers. 
This type of clinical investigation is the essential 
next step after identifYing independent risk factors 
to correctly select the patients for transplantation 
and also to determine the true effect of chemother-
apy in the prevention of tumor recurrence. Our 
results indicate that 1) patients with grades 1 and 2 
are effectively treated with liver transplantation, 2) 
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patients with grades 4 and 5 are poor candidates for 
liver transplantation, 3) patients with grade 1 do 
no't benefit from adjuvant chemotherapy, and 4) 
patients with grades 2 and 3 should be studied sys-
tematically to determine the effect of adjuvant che-
motherapy. Our analysis of the 79 patients with 
grades 2 and 3 did not reveal a~y significant effect of 
neoadjuvant and adjuvant chemotherapy on tumor 
recurrence. 
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Figure 2. Actuarial tumor-free survival stratified by p TNM stages. 
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